NB003
GISTAR-1
Ningbo Newbay Technology Development · Phase 2/3 · Recruiting · Enrollment 255
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| NB003 15 mg BID (Part 1) | 3L GIST after imatinib and sunitinib | 15 mg | ITT | regorafenib 160 mg | n/r |
| Regorafenib 160 mg | 3L GIST | 160 mg | ITT | n/r | n/r |
No efficacy figure is in this file for this study.